（来源：新华日报） 常州翌晶氢能科技有限公司车间 □ 本报记者 徐冠英 杨易臻 总决赛成长企业组金奖得主苏州易缆微半导体技术有限公司，专注于光通信领域光子芯片的研发、设计 与生产。公司创始人、董事长、总经理陈伟告诉记者，下一代智能算力中心对高性能、高速率、高可靠 性光子芯片的需求将持续攀升。9月，在中国国际光电博览会上，公司发布的一款硅光异质集成薄膜铌 酸锂单波400Gbps光子芯片，比目前算力中心使用的主流光子芯片提速2—4倍。 同样在总决赛斩获金奖的苏州元相微科技有限责任公司，属于初创企业组，从事表面动态电子显微镜研 发。面对半导体制造中最具挑战的原子级缺陷检测难题，研发团队利用自主开发的表面量子波动显微技 术，推出一款晶圆检测设备。该设备实现大视场、高通量的"非扫描"动态成像，能在不损伤样品的前提 下进行测试，为国产芯片提升良率提供关键的"火眼金睛"。 在总决赛获得铜奖的苏州湃芮生物科技有限公司，聚焦靶向RNA修饰的创新药物开发。针对抗癌药物 导致的手足综合征，该公司研发的一款小分子RNA m6A调控剂，目前在国内11家医院临床研究中心同 时开展Ⅱ期临床试验。"RNA修饰"是该公司董事长王靖方从事基础科 ...

Core Insights - Four Jiangsu enterprises won awards at the 14th China Innovation and Entrepreneurship Competition in the biomedicine national contest, with one Jiangsu company taking the only first prize in the growth enterprise category [1] - The competition featured 228 companies, with 20 from Jiangsu, highlighting the region's strong performance in innovation [1] - A total of 17 Jiangsu companies received the "Excellent Enterprise" title, showcasing the province's competitive edge in the biotech sector [1] Company Highlights - Suzhou Pairui Biotechnology Co., Ltd. won the first prize in the growth enterprise category for its project on "Targeted RNA Modification for Innovative Drug Development," focusing on a small molecule RNA m6A regulator for cancer treatment, currently in phase II clinical trials across 10 hospitals [1] - Suzhou Borui Chuanghe Pharmaceutical Co., Ltd. received the third prize in the growth enterprise category, specializing in radioactive targeted drugs (RDC) for precise tumor diagnosis and treatment, with several proprietary radiopharmaceuticals in clinical stages [1] - Qingyuan Zhixin (Suzhou) Biotechnology Co., Ltd. won the second prize in the startup category for its "AI Manufacturing: Organ Revolution - 3D Organ Full-Stack Solution," which aims to create human-like organs through 3D bioprinting for drug testing and innovative drug development [1] - Ansheng Kangtai Pharmaceutical (Nantong) Co., Ltd. secured the third prize in the startup category with its project targeting acute inflammatory diseases through universal cell products, addressing clinical challenges in genetic diseases and immune rejection [1]